Prostate Cancer Screening and the Associated Controversy

Surgical Clinics of North America

Volumn 95, Issue 5, 2015, Pages 1023-1039

  Tabayoyong, William ^a   Abouassaly, Robert ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; FOLLOW UP; HISTORY; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; UNITED STATES; ADVERSE EFFECTS; BLOOD; EARLY DIAGNOSIS; MALE; MASS SCREENING; PROCEDURES; PROSTATIC NEOPLASMS;

EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84940614202     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2015.05.001     Document Type: Review

References (76)

1. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Gjertson C.K., Albertsen P.C. Use and assessment of PSA in prostate cancer. Med Clin North Am 2011, 95(1):191-200.
3. Sakr W.A., Haas G.P., Cassin B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993, 150(2 Pt 1):379-385.
4. Johansson J.E., Adami H.O., Andersson S.O., et al. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989, 1(8642):799-803.
5. Johansson J.E., Adami H.O., Andersson S.O., et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992, 267(16):2191-2196.
6. Johansson J.E., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997, 277(6):467-471.
7. Johansson J.E., Andrén O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 2004, 291(22):2713-2719.
8. Popiolek M., Rider J.R., Andrén O., et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 2013, 63(3):428-435.
9. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998, 280(11):975-980.
10. Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293(17):2095-2101.
11. Brawley O.W. Prostate cancer epidemiology in the United States. World J Urol 2012, 30(2):195-200.
12. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002, 168(3):906-913.
13. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8(4):268-278.
14. Wang M.C., Valenzuela L.A., Murphy G.P., et al. Purification of a human prostate specific antigen. Invest Urol 1979, 17(2):159-163.
15. Kuriyama M., Wang M.C., Papsidero L.D., et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980, 40(12):4658-4662.
16. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317(15):909-916.
17. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324(17):1156-1161.
18. Brawer M.K., Chetner M.P., Beatie J., et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992, 147(3 Pt 2):841-845.
19. Merrill R.M., Stephenson R.A. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000, 163(2):503-510.
20. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. 2015. Available at: Accessed January 17, 2015. http://seer.cancer.gov/faststats/selections.php?series=cancer.
21. Tarone R.E., Chu K.C., Brawley O.W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000, 11(2):167-170.
22. Etzioni R., Legler J.M., Feuer E.J., et al. Cancer surveillance series: interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999, 91(12):1033-1039.
23. Walsh P.C. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Urol 2000, 163(1):364-365.
24. Feuer E.J., Merrill R.M., Hankey B.F. Cancer surveillance series: interpreting trends in prostate cancer-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999, 91(12):1025-1032.
25. Etzioni R., Gulati R., Tsodikov A., et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012, 118(23):5955-5963.
26. Etzioni R., Tsodikov A., Mariotto A., et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008, 19(2):175-181.
27. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270(8):948-954.
28. Dong F., Reuther A.M., Magi-Galluzzi C., et al. Pathologic stage migration has slowed in the late PSA era. Urology 2007, 70(5):839-842.
29. Li J., Djenaba J.A., Soman A., et al. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012, 2012:691380.
30. Welch H.G., Albertsen P.C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009, 101(19):1325-1329.
31. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004, 350(22):2239-2246.
32. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267(16):2215-2220.
33. Holmstrom B., Johansson M., Bergh A., et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009, 339:b3537.
34. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360(13):1310-1319.
35. Andriole G.L., Crawford E.D., Grubb R.L., et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104(2):125-132.
36. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.
37. Schroder F.H., Hugosson J., Roobol M.J., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
38. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, 384(9959):2027-2035.
39. U.S.Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149(3):185-191.
40. Moyer V.A., U.S.Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(2):120-134.
41. AUA Health Policy Brief, AUA Response to USPSTF PSA Recommendations. 2011. Available at: Accessed January 17, 2015. http://www.auanet.org/advnews/hpbrief/view.cfm?i=649%26a=1806.
42. Messing E, Albertson P, Andriole GL Jr, et al. SUO's response to the USPSTF. 2011. Available at: Accessed January 17, 2015. http://suonet.org/news/SUO%20precon%20news%202011.pdf.
43. Chou R., Croswell J.M., Dana T., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155(11):762-771.
44. Cooperberg M.R. Implications of the new AUA guidelines on prostate cancer detection in the U.S. Curr Urol Rep 2014, 15(7):420.
45. Catalona W.J., D'Amico A.V., Fitzgibbons W.F., et al. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012, 157(2):137-138.
46. Pinsky P.F., Blacka A., Kramer B.S., et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010, 7(4):303-311.
47. Pinsky P.F., Andriole G.L., Kramer B.S., et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol 2005, 173(3):746-750. [discussion: 750-1].
48. Etzioni R.D., Thompson I.M. What do the screening trials really tell us and where do we go from here?. Urol Clin North Am 2014, 41(2):223-228.
49. Draisma G., De Koning H.J. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003, 92(Suppl 2):106-111.
50. US Preventive Services Task Force Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151(10):716-726. W-236.
51. U.S.Preventive Services Task Force Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149(9):627-637.
52. Towler B., Irwig L., Glasziou P., et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. BMJ 1998, 317(7158):559-565.
53. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11(8):725-732.
54. Ganz P.A., Barry J.M., Burke W., et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012, 156(8):591-595.
55. Scosyrev E., Wu G., Mohile S., et al. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012, 118(23):5768-5776.
56. Gulati R., Tsodikov A., Etzioni R., et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer 2014, 120(22):3519-3526.
57. Aslani A., Minnillo B.J., Johnson B., et al. The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 2014, 191(6):1737-1742.
58. Cohn J.A., Wang C.E., Lakeman J.C., et al. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 2014, 32(1):41.e23-41.e30.
59. Bhindi B., Mamdani M., Kulkarni G.S., et al. Impact of the U.S. Preventive Services Task Force Recommendations Against PSA Screening on Prostate Biopsy and Cancer Detection Rates. J Urol 2015, 193(5):1519-1524.
60. Perez T.Y., Danzig M.R., Ghandour R.A., et al. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices. Urology 2015, 85(1):85-91.
61. Maurice M.J., Abouassaly R. Patient opinions on prostate cancer screening are swayed by the United States Preventative Services Task Force recommendations. Urology 2014, 84(2):295-299.
62. Ulmert D., Cronin A.M., Björk T., et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008, 6:6.
63. Lilja H., Cronin A.M., Dahlin A., et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011, 117(6):1210-1219.
64. Vickers A.J., Cronin A.M., Björk T., et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010, 341:c4521.
65. Vickers A.J., Ulmert D., Sjoberg D.D., et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013, 346:f2023.
66. Klotz L., Vesprini D., Sethukavalan P., et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015, 33(3):272-277.
67. Roemeling S., Roobol M.J., de Vries S.H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007, 51(5):1244-1250. [discussion: 1251].
68. Soloway M.S., Soloway C.T., Williams S., et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008, 101(2):165-169.
69. Kane C.J., Im R., Amling C.L., et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010, 76(3):695-700.
70. Greene K.L., Albertsen P.C., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182(5):2232-2241.
71. Carter H.B., Albertsen P.C., Barry M.J., et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013, 190(2):419-426.
72. Qaseem A., Barry M.J., Denberg T.D., et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013, 158(10):761-769.
73. Basch E., Oliver T.K., Vickers A., et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012, 30(24):3020-3025.
74. Carroll P.R., Parsons J.K., Andriole G., et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 2014, 12(9):1211-1219. [quiz: 1219].
75. Loeb S., Catalona W.J. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014, 6(2):74-77.
76. Carlsson S., Maschino A., Schröder F., et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol 2013, 64(5):693-699.